Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects

In 16 patients with Raynaud's phenomenon a placebo-controlled single-dose study was performed on the hemodynamic effects of 10 mg nifedipine, sublingually administered, followed by an open eight-week study on the therapeutic efficacy of chronic oral nifedipine, 10 mg qid. After the acute sublingual nifedipine administration, a pronounced objective improvement of finger skin (P = .013) and forearm muscle blood flow (P = .04) during a standard finger-cooling test was found. During the chronic oral study the improvement in objective efficacy parameters disappeared, except for laser Doppler estimated shunt flow (P = .07). The acute hemodynamic effects did not predict the long-term results in individual patients. Patients with systemic sclerosis reacted as well as patients with primary Raynaud's phenomenon. This study shows that orally administered nifedipine does not convey long-term objective benefit to patients with Raynaud's phenomenon. The apparent increase in vasodilation during acute administration suggests that sublingual nifedipine prophylactically or during a vasospastic attack may be more useful.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. A. Fontenelle, C. Kayser, M. L. C. Pucinelli, and L. E. C. Andrade Cold stimulus fingertip lacticemy test an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis Rheumatology, January 1, 2008; 47(1): 80 - 83. [Abstract] [Full Text] [PDF]

				A. E. Thompson and J. E. Pope Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis Rheumatology, February 1, 2005; 44(2): 145 - 150. [Abstract] [Full Text] [PDF]

				T. J. M. Cleophas and M. G. Niemeyer Raynaud's Syndrome, an Enigma After 130 Years Angiology, March 1, 1993; 44(3): 196 - 209. [Abstract] [PDF]